Mariner’s RAPT Therapeutics RAPT Stock Holding History

Mariner’s Portfolio RAPT Stock Details RAPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-1,309	Closed	-$207K	–	2865
2022 Q4	$207K	Buy	+1,309	New	+$209K	﹤0.01%	2329

Other funds holding RAPT

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Column Group San Francisco, California $101M AUM 290.34% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

GPP

Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Mariner's RAPT Position: Q1 2023 in Review

Mariner sold out of RAPT Therapeutics (RAPT) in Q1 2023, closing a stake of 1,309 shares — an estimated $207K sold.

Mariner first reported a position in RAPT in Q4 2022 and held it in 1 quarter. The position peaked at $207K in Q4 2022. 106 funds tracked by Wall St. Rank hold RAPT as of Q1 2023.

Mariner reported no remaining RAPT Therapeutics position as of Q1 2023 after selling out during the quarter.
Mariner sold 1,309 RAPT Therapeutics shares in Q1 2023, an estimated $207K.
Mariner first reported a position in RAPT Therapeutics in Q4 2022 and held it in 1 quarter.
Mariner's RAPT Therapeutics position peaked at $207K in Q4 2022.
106 funds tracked by Wall St. Rank held RAPT Therapeutics as of Q1 2023.

Based on Mariner's 13F filing for Q1 2023, filed 15 May 2023.